Skip to main content
SpringerLink
Log in

Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The interaction of tamoxifen and clomifene with membrane binding sites for the cholinergic ligand quinuclidinyl benzilate (QNB) and the dihydropyridine calcium antagonist nitrendipine was studied. Both tamoxifen and clomifene competed with [3H]-QNB and [3H]-nitrendipine for their binding to the receptor in the membrane fractions from the urinary bladder and myometrium. The extent of inhibition as judged by the Ki values for both antiestrogens was similar at both receptor sites. The data suggest that the antiproliferative effects of tamoxifen may involve not only the intracellular estrogen-receptor system but also receptors for neurotransmitters and membrane calcium channels

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Batra S (1985) Characterization of [3H]-nitrendipine binding to uterine smooth muscle plasma membrane and its relevance to inhibition of calcium entry. Br J Pharmacol 27: 57

    Google Scholar 

  2. Batra S (1987) Comparison of muscarinic acetylcholine binding in the urinary bladder and submandibular gland of the rabbit. Eur J Pharmacol 138: 83

    Article  PubMed  CAS  Google Scholar 

  3. Batra S, Popper L (1989) Characterization of membrane calcium channels in the nonpregnant and pregnant human uterus. Gynecol Obstet Invest 27: 57

    Article  PubMed  CAS  Google Scholar 

  4. Batra S, Sjöberg N-O, Thorbert G (1978) Estrogen and progesterone interactions in the rabbit uterus in vivo after steroid administration. Endocrinology 102: 268

    Article  PubMed  CAS  Google Scholar 

  5. Bratherton DG, Brown CH, Buchanan R, Hall V, Pillers EMK, Wheeler TK, Williams CJ (1984) A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bdversus 20 mg bd. Br J Cancer 50: 199

    PubMed  CAS  Google Scholar 

  6. Cheng YC, Prusoff NH (1983) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099

    Article  Google Scholar 

  7. Criss WE, Kaiuchi S (1982) Calcium: calmodulin and cancer. Fed Proc 41: 2289

    PubMed  CAS  Google Scholar 

  8. Goodlad RA, Wright NA (1989) Peptides and epithelial growth regulation. Experientia 56: 180–191

    CAS  Google Scholar 

  9. Greenberg DA, Carpenter CL, Messing RO (1987) Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 47: 70

    PubMed  CAS  Google Scholar 

  10. Hohn KV, Onoda JM, Diglio DA, Sloane BF (1983) Calcium channel blockers: potential antimetastatic agents. Proc Soc Exp Biol Med 174: 16

    Google Scholar 

  11. Jacobs SC, Slory MT (1988) Exocrine secretion of epidermal growth factor by rat prostate: effect of adrenergic agents, cholinergic agents and vasoactive intestinal peptide. Prostate 13: 79

    Article  PubMed  CAS  Google Scholar 

  12. Jordan VC (1984) Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245

    PubMed  CAS  Google Scholar 

  13. Kroegar EA, Brandes LJ (1985) Evidence that tamoxifen is a histamine antagonist. Biochem Biophys Res Commun 130: 750

    Article  Google Scholar 

  14. Lam H-YP (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118: 27

    Article  PubMed  CAS  Google Scholar 

  15. Lazo JS, Schwartz PE, Maclusky MJ, Labaree DC, Eisenfeld AJ (1984) Antiproliferative actions of tamoxifen of human ovarian carcinomas in vitro. Cancer Res 44: 2266

    CAS  Google Scholar 

  16. Lippman ME, Bates S, Dicksson RB, Knabbe C, Huff K, Swain S, McManaway M, Bronzert D, Kasid A, Gelmann EP (1986) Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7: 59

    Article  PubMed  CAS  Google Scholar 

  17. Lipton A (1987) The anti-oestrogen tamoxifen is a calcium antagonist in perfused rat mesentery. Cancer Chemother Pharmacol 20: 125

    Article  PubMed  CAS  Google Scholar 

  18. Peterson GL (1979) A simplification of the protein assay method of Lowry et al. which is more generally acceptable. Anal Biochem 83: 346

    Article  Google Scholar 

  19. Runge H-M, Teufel G, Neulen J, Geyer H, Pfleiderer A (1986) In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy. Cancer Chemother Pharmacol 16: 48

    Article  Google Scholar 

  20. Takuwa N, Ganz M, Takuwa Y, Sterzel RB, Rusmussen H (1989) Studies of the mitrogenic effect of serotonin in rat renal mesangial cells. Am J Physiol 257: 431–439

    Google Scholar 

  21. Watts CKW, Murphy LC, Sutherland RL (1984) Microsomal binding sites for nonsteroidal anti-estrogens in MCF-7 human mammary carcinoma cells. J Biol Chem 259: 4223–4229

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University Hospital, S-221 85, Lund, Sweden

    Satish Batra

Authors
  1. Satish Batra
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batra, S. Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes. Cancer Chemother Pharmacol 26, 310–312 (1990). https://doi.org/10.1007/BF02897237

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02897237

Keywords

Search

Navigation